Karnon, Jon; Jones, Trefor - In: PharmacoEconomics 21 (2003) 7, pp. 513-525
Background: Letrozole is a third-generation aromatase inhibitor that is a feasible alternative to tamoxifen as a first-line hormonal therapy for patients with advanced breast cancer. Objective: This paper presents the results of an economic evaluation comparing letrozole and tamoxifen as...